ProPhase Labs (PRPH) Competitors

vTv Therapeutics (NASDAQ:VTVT) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Which has more volatility & risk, VTVT or PRPH?

vTv Therapeutics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.78, suggesting that its stock price is 178% less volatile than the S&P 500.

Which has preferable earnings and valuation, VTVT or PRPH?

vTv Therapeutics has higher earnings, but lower revenue than ProPhase Labs. vTv Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	67.01	-$18.46M	-$3.12	-6.87
ProPhase Labs	$6.77M	2.66	-$53.36M	-$1.26	-0.34

Does the media refer more to VTVT or PRPH?

In the previous week, ProPhase Labs had 5 more articles in the media than vTv Therapeutics. MarketBeat recorded 8 mentions for ProPhase Labs and 3 mentions for vTv Therapeutics. ProPhase Labs' average media sentiment score of 0.89 beat vTv Therapeutics' score of 0.64 indicating that ProPhase Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProPhase Labs	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend VTVT or PRPH?

vTv Therapeutics currently has a consensus target price of $35.50, suggesting a potential upside of 65.69%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe vTv Therapeutics is more favorable than ProPhase Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
ProPhase Labs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do insiders and institutionals hold more shares of VTVT or PRPH?

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are held by institutional investors. 1.3% of vTv Therapeutics shares are held by insiders. Comparatively, 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is VTVT or PRPH more profitable?

vTv Therapeutics' return on equity of -179.75% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-179.75%	-55.91%
ProPhase Labs	N/A	-262.42%	-76.48%

Summary

vTv Therapeutics beats ProPhase Labs on 9 of the 15 factors compared between the two stocks.